2Q Earnings Presentation August 2025 Copyright © 2025 agilon health. Confidential internal document containing proprietary information. Do not distribute. Disclaimers and Forward-Looking Statements FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION Statements in this presentation that are not historical factual statements are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-look ...

Centene Corporation CNC will release earnings results for the second quarter before the opening bell on Friday, July 25.Analysts expect the Saint Louis, Missouri-based company to report quarterly earnings at 23 cents per share, down from $2.42 per share in the year-ago period. Centene is projected to report quarterly revenue of $44.2 billion, compared to $39.84 billion a year earlier, according to data from Benzinga Pro.On July 1, Centene withdrew its previous 2025 GAAP and adjusted diluted EPS guidance, in ...

NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Centene Corporation ("Centene" or the "Company")(NYSE: CNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll- free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Centene and certain of its off ...

Wall Street analysts forecast that Centene (CNC) will report quarterly earnings of $0.68 per share in its upcoming release, pointing to a year-over-year decline of 71.9%. It is anticipated that revenues will amount to $44.27 billion, exhibiting an increase of 11.1% compared to the year-ago quarter.Over the last 30 days, there has been a downward revision of 57.3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of t ...

Core Viewpoint - Rosen Law Firm has announced the filing of a class action lawsuit on behalf of purchasers of Centene Corporation securities between December 12, 2024, and June 30, 2025, alleging misleading statements regarding the company's financial performance and enrollment rates [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that during the Class Period, Centene's management provided investors with overly positive information regarding expected revenue guidance and adjusted diluted earnings per share (EPS) for the 2025 fiscal year [5]. - Defendants allegedly made confident statements about Centene's enrollment and morbidity rates, as well as strong retention rates in its Medicare business, while concealing material adverse facts about the true state of these metrics [5]. Group 2: Participation Information - Investors who purchased Centene common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4].

Core Viewpoint - Centene experienced a significant drop in stock price, closing down over 40% on July 2, resulting in a loss of over $11 billion in market capitalization, with competitors also facing declines [1][2][5] Group 1: Financial Impact - The drop in Centene's shares was primarily due to the withdrawal of its 2025 full-year guidance, indicating a more challenging financial outlook [2][4] - The company received data indicating lower growth in the ACA exchange market and higher morbidity among enrollees, leading to fewer and sicker patients [3][4] - The expected impact on Centene's 2025 diluted earnings per share (EPS) is a reduction of $2.75, which is 38% of the previously expected EPS of greater than $7.25 [4][5] Group 2: Market Valuation - Despite the significant stock sell-off, Wall Street analysts see a more attractive valuation for Centene, with a 12-month price target of $68.87, implying a potential upside of 108.31% from the current price [5][6] - The average price target post-guidance withdrawal is $51, suggesting a 53% upside, which is higher than the 32% average upside prior to the drop [6][7] Group 3: Regulatory Environment - The recent legislation signed into law includes $1 trillion in cuts to Medicaid, which accounted for approximately 46% of Centene's revenue last quarter, potentially leading to 10.3 million to 11.8 million fewer Medicaid recipients over the next decade [8][9] - The reduction in expected Medicaid users could have a more significant and lasting impact on Centene compared to the ACA exchange enrollment issues, which only made up 20% of the firm's total revenue last quarter [9]

Core Viewpoint - Centene Corporation is under investigation for potential violations of federal securities laws due to allegations of providing misleading business information, which has led to significant stock price decline following the withdrawal of its earnings guidance [1][4]. Company Overview - Centene is a managed healthcare company that specializes in government-sponsored programs such as Medicaid and Medicare, as well as health insurance plans on individual exchanges and commercial marketplaces [3]. Alleged Wrongdoing - On July 1, 2025, Centene announced its decision to withdraw its 2025 earnings guidance, citing declining market growth in 22 out of the 29 states it operates in. The company indicated that health risks in these states were much higher than previously anticipated in its risk adjustment calculations [4]. - Following this announcement, Centene's stock price dropped by $22.87 per share, representing a 40.37% decline, closing at $33.78 per share on July 2, 2025 [4].

Group 1 - Centene Corporation is under investigation for potential securities fraud and unlawful business practices involving its officers and directors [1] - On July 1, 2025, Centene withdrew its 2025 GAAP and adjusted diluted earnings per share guidance due to underperformance in market growth across 22 out of 29 states and higher-than-expected health risks affecting revenue calculations [2] - Following the announcement, Centene's stock price dropped by $22.87, or 40.37%, closing at $33.78 per share on July 2, 2025 [3] Group 2 - Pomerantz LLP is a prominent law firm specializing in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Centene Corporation is facing an investigation regarding potential securities fraud and unlawful business practices following its withdrawal of earnings guidance due to disappointing market growth and higher-than-expected health risks [1][3]. Group 1: Company Performance - On July 1, 2025, Centene announced the withdrawal of its 2025 GAAP and adjusted diluted earnings per share (EPS) guidance, citing that market growth in 22 out of 29 states was not meeting expectations [3]. - The company indicated that the overall health risks in these states were significantly higher than anticipated, impacting its risk adjustment revenue calculations [3]. Group 2: Market Reaction - Following the announcement, Centene's stock price experienced a significant decline, falling by $22.87 per share, or 40.37%, closing at $33.78 per share on July 2, 2025 [4]. Group 3: Legal Investigation - Pomerantz LLP is investigating claims on behalf of Centene investors regarding possible securities fraud or other unlawful business practices by the company and its officers or directors [1].

Market Overview - Markets ended higher on Wednesday, with the S&P 500 and Nasdaq Composite indices advancing by 0.47% and 0.94%, respectively, while the Dow Jones Industrial Average dropped by 10.52 points [1] - Market sentiment was positively influenced by a trade accord between the United States and Vietnam, easing concerns over prolonged trade tensions [1] Economic Indicators - A recent ADP report indicated an unexpected drop in private payrolls for June, with the private sector losing 33,000 jobs, suggesting potential challenges for the U.S. economy [2] - This decline in job numbers has raised scrutiny from investors, particularly in light of the Federal Reserve's cautious stance on interest rates [2] Investment Strategy - In the current macroeconomic environment, focusing on companies with strong financial fundamentals is crucial [3] - Relying solely on sales and earnings metrics may not yield long-term returns; a deeper analysis of a company's financial health and stability is essential for sustainable investment growth [3] Financial Analysis - A critical analysis of a company's financial background, including coverage ratios, is necessary for informed investment decisions [4] - The Interest Coverage Ratio is a key indicator used to evaluate a company's ability to pay interest on its debt, ensuring it is not over-leveraged [4][6] Interest Coverage Ratio Insights - The Interest Coverage Ratio is calculated as Earnings before Interest & Taxes (EBIT) divided by Interest Expense [5] - A ratio lower than 1.0 indicates a company may struggle to meet its interest obligations, while a higher ratio suggests a stronger financial position [9] Company Performance - Hudbay Minerals Inc. (HBM), Sterling Infrastructure, Inc. (STRL), Molina Healthcare, Inc. (MOH), and Vertiv Holdings Co (VRT) have strong interest coverage ratios, indicating solid financial footing [10] - HBM and STRL posted over 40% EPS growth estimates, while VRT shows a growth potential of 24.9% [10] - MOH projects 8.4% sales growth and 7.9% EPS growth, despite a 19.3% stock decline over the past year [10] Stock Screening Criteria - Stocks should have an Interest Coverage Ratio greater than the industry average, a favorable Zacks Rank, and a VGM Score of A or B for better investment results [11] - Additional criteria include a minimum stock price of $5, strong historical and projected EPS growth, substantial trading volume, and a Zacks Rank of 1 or 2 [12][13] Company Highlights - Hudbay Minerals has a trailing four-quarter earnings surprise of 50% on average, with a Zacks Consensus Estimate suggesting growth of 9.2% in sales and 41.7% in EPS [14] - Sterling Infrastructure has a trailing four-quarter earnings surprise of 11.5% on average, with a projected EPS growth of 41.2% [15] - Molina Healthcare's Zacks Consensus Estimate indicates growth of 8.4% in sales and 7.9% in EPS [16] - Vertiv Holdings has a trailing four-quarter earnings surprise of 10.4% on average, with projected growth of 18.8% in sales and 24.9% in EPS [17]